nemo I Inhibitors
Nemo I Inhibitors belong to a distinctive chemical class that has garnered substantial attention in the realm of molecular research. Characterized by their unique structural features, these inhibitors are specifically designed to modulate a certain biological pathway. The term "nemo I" refers to the target molecule within the intricate signaling cascade, which plays a critical role in various cellular processes. Chemically, the inhibitors typically possess a carefully crafted scaffold that facilitates their interaction with the active site of the nemo I molecule. This interaction is crucial for the inhibition of downstream signaling events.
The design of nemo I inhibitors involves a meticulous understanding of the target's active site geometry and binding preferences. Researchers often employ computational modeling and structural studies to refine the binding interactions and optimize the inhibitory potency of these compounds. The development of nemo I inhibitors represents a significant advancement in chemical biology, offering researchers a valuable tool to dissect the intricacies of cellular pathways and unravel the functional relevance of nemo I in various physiological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits Nemo by blocking the activation of the IκB kinase complex, thus preventing the phosphorylation and degradation of IκBα. This leads to the inhibition of NF-κB signaling pathway. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits Nemo through inhibiting the NEDD8-activating enzyme (NAE), preventing neddylation of proteins including Cullin-RING ligases. This leads to the suppression of NF-κB activation. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 inhibits Nemo by blocking the interaction of Nemo with the ubiquitin-conjugating enzyme Ubc13, thereby inhibiting the activation of the NF-κB pathway. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IMD-0354 inhibits Nemo by disrupting the binding of Nemo to IKKβ, resulting in the inhibition of the IKK complex and subsequently blocking the NF-κB pathway activation. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
SC-514 inhibits Nemo by targeting IκB kinase, leading to the prevention of IκBα phosphorylation and subsequent suppression of NF-κB activation. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide inhibits Nemo by preventing the ubiquitination and degradation of IκBα, thus sequestering NF-κB in the cytoplasm and preventing its translocation to the nucleus. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $124.00 $526.00 | 55 | |
Bay 11-7085 inhibits Nemo by inhibiting the activation of IKKβ, which leads to the prevention of IκBα phosphorylation and the subsequent inhibition of NF-κB signaling. | ||||||
ML 120B Dihydrochloride | 783348-36-7 (free base) | sc-487759 | 5 mg | $380.00 | ||
MLN120B inhibits Nemo by disrupting the interaction between Nemo and IKKβ, resulting in the inhibition of the NF-κB pathway activation. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
Celastrol inhibits Nemo by suppressing the activation of IKKβ, leading to the inhibition of IκBα phosphorylation and subsequent inhibition of NF-κB signaling. | ||||||